Both enalapril and losartan attenuate sarcolemmal Na+-K+-ATPase remodeling in failing rat heart due to myocardial infarction

Canadian Journal of Physiology and Pharmacology
Xiaobing GuoN S Dhalla

Abstract

To investigate the mechanisms underlying the depressed sarcolemmal (SL) Na(+)-K(+)-ATPase activity in congestive heart failure (CHF), different isoforms and gene expression of Na(+)-K(+)-ATPase were examined in the failing left ventricle (LV) at 8 weeks after myocardial infarction (MI). In view of the increased activity of renin-angiotensin system (RAS) in CHF, these parameters were also studied after 5 weeks of treatment with enalapril (10 mg x kg-1 x day-1), an angiotensin-converting enzyme inhibitor, and losartan (20 mg.kg-1.day-1), an angiotensin II type 1 receptor antagonist, starting at 3 weeks after the coronary ligation in rats. The infarcted animals showed LV dysfunction and depressed SL Na(+)-K(+)-ATPase activity. Protein content and mRNA levels for Na(+)-K(+)-ATPase alpha2 isoform were decreased whereas those for Na(+)-K(+)-ATPase alpha3 isoform were increased in the failing LV. On the other hand, no significant changes were observed in protein content or mRNA levels for Na(+)-K(+)-ATPase alpha1 and beta1 isoforms. The treatment of infarcted animals with enalapril or losartan improved LV function and attenuated the depression in Na(+)-K(+)-ATPase alpha2 isoform as well as the increase in alpha3 isoform, at both the p...Continue Reading

References

Mar 1, 1992·The American Journal of Physiology·I M DixonN S Dhalla
Jul 14, 1988·The New England Journal of Medicine·M A PfefferE Braunwald
Jun 18, 1998·American Heart Journal·M K BaigM Gheorghiade
Aug 26, 1998·Journal of Molecular and Cellular Cardiology·S O SembO M Sejersted
Jul 9, 2002·Journal of Molecular and Cellular Cardiology·Jingwei WangNaranjan S Dhalla
May 24, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Adel B ElmoselhiNaranjan S Dhalla
Dec 4, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Qiming ShaoNaranjan S Dhalla
Feb 1, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Qiming ShaoNaranjan S Dhalla
May 17, 2006·Journal of Cardiovascular Pharmacology and Therapeutics·Naranjan S DhallaRamesh K Goyal
Sep 15, 2006·The Canadian Journal of Cardiology·Jarmila MachackovaNaranjan S Dhalla

❮ Previous
Next ❯

Citations

Oct 15, 2008·Cardiovascular Research·Naranjan S DhallaParamjit S Tappia
Jun 21, 2013·The Journal of Endocrinology·Milan ObradovicEsma R Isenovic
Jan 27, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Weihua ZhangNaranjan S Dhalla
Sep 6, 2012·Journal of Cellular and Molecular Medicine·Andrea BabickNaranjan S Dhalla
Jun 17, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·O S MichaelL A Olatunji

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Cardiac Glycosides

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit na+/k+-atpase. Discover the latest research on cardiac glycosides heres.